PRODUCT LITERATURE

Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis

---

The safety and efficacy of febuxostat in patients with stage 4–5 chronic kidney disease (CKD) are still unclear owing to a lack of studies in these patients. Therefore, we aimed to evaluate the effect of febuxostat on renal function, general safety, and efficacy in gout patients with stage 4–5 CKD

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Festaric
Febuxostat
Chronic Kidney Disease
Urate

Specific Detail Info

Korean J Intern Med 2020;35(4):998-1003

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment